It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kaleido Biosciences Inc (KLDO) USD0.001

Sell:$6.31 Buy:$6.32 Change: $0.50 (8.51%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Change: $0.50 (8.51%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Change: $0.50 (8.51%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Its proprietary product platform includes ex vivo screening of microbiome samples from healthy volunteers, ex vivo testing of patient microbiome samples and advancement of its MMT candidates into non- Investigational New Drug Application (IND) human clinical studies. Its ex vivo screening process combines advances in drug discovery with microbiome science.

Contact details

18 Crosby Dr
United States
+1 (617) 6749000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$270.42 million
Shares in issue:
42.52 million
United States
US dollar

Key personnel

  • Michael Bonney
    Chairman of the Board
  • Daniel Menichella
    President, Chief Executive Officer, Principal Executive Officer
  • William Duke
    Chief Financial Officer
  • Jerald Korn
    General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.